Sankala Group’s Protagonist Therapeutics PTGX Stock Holding History

Sankala Group’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.47K	Hold	60	–	–	0.01%	404
2026 Q1	$6.07K	Hold	60	–	–	0.01%	425
2025 Q4	$5.53K	Buy	+60	New	+$4.91K	﹤0.01%	446

Other funds holding PTGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Sankala Group's PTGX Position: Q2 2026 in Review

Sankala Group held its Protagonist Therapeutics (PTGX) position steady in Q2 2026 at 60 shares worth $9.47K. The position accounts for 0.01% of the portfolio, ranked #404.

Sankala Group first reported a position in PTGX in Q4 2025 and has held it in 3 quarters since. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

Sankala Group held 60 shares of Protagonist Therapeutics worth $9.47K as of Q2 2026.
Sankala Group left its Protagonist Therapeutics share count unchanged in Q2 2026.
Protagonist Therapeutics made up 0.01% of Sankala Group's portfolio in Q2 2026, its #404 holding.
Sankala Group first reported a position in Protagonist Therapeutics in Q4 2025 and has held it in 3 quarters since.
343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Sankala Group's 13F filing for Q2 2026, filed 18 Aug 2026.